echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Perjury? MSD and Gilead patent lawsuits have changed!

    Perjury? MSD and Gilead patent lawsuits have changed!

    • Last Update: 2016-05-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Medical Rubik's cube data 2016-05-04 a jury of a federal court in the United States announced on March 22 that it supported the judge's judgment, finding that the two sofibwe patents declared by mosadon were valid, and had the right to claim a certain proportion of sovaldi / harvoni sales share from Gilead as compensation However, in terms of the specific amount of compensation, the jury did not connive at the lion's big mouth Compared with murshadong's claim for $2 + billion, the jury finally thought that Gilead could deduct $15 billion from sovaldi / harvoni's $20 billion sales revenue, and only pay 4% of $5 billion to murshadong, that is, a mere $200 million compensation Maybe before MSD can express his disappointment at the result, the plot reverses.. Dr Phil durette is a retired scientist from MSD Gilead and a key witness in the MSD Gilead patent dispute He testified that it was his early scientific research that led to sofibwe's discovery, while mosadon, who had planned to acquire pharmaset, was ahead of Gilead with $11 billion in 2011 Gilead believed that durette had stolen the research results of pharmaset, and in refuting durette, he adduced that: "mosadong held a conference call with pharmaset on the acquisition proposal in 2004, durette also participated in the conference call, and participated in the discussion of pharmaset's hepatitis C drugs Durette initially told the jury not to attend the conference call, then withdrew his testimony, saying he had forgotten that he had attended the conference call at that time " Mr moshadong responded that durette's change of testimony was not intentional He only checked his personal Notepad to confirm that he did attend the conference call Judge labson Freeman was angry at durette ' Once the case is reiterated, Gilead's previous infringement judgment may be revoked, and the compensation may also be a purchase and sale But even $200 million in cash is not enough to excite Gilead, whose sales of hepatitis C drugs have declined in 2016q1 In the dilemma of poor transformation, Gilead continued to work in the field of liver diseases and shifted its research and development focus to hepatitis B and other liver diseases (NASH), including submitting the listing application for TAF treatment of hepatitis B, and acquiring nimbus Apollo with a large amount of US $1.2 billion
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.